Deprecated: The each() function is deprecated. This message will be suppressed on further calls in /home/zhenxiangba/zhenxiangba.com/public_html/phproxy-improved-master/index.php on line 456
BR9407866A - Composto processos para inibiçao de 5 -redufase ou isoenzimas da mesma paratratamento de condiçoes de acne vulgar alopécia androgènica hirsutismo feminino hiperplasia prostática benigna prostatite e para o tratamento e/ou prevençao do cancer da próstata para interrupçao e reversao de alopécia androgènica e promoçao do crescimento de cabelo em um mamifero e para inibiçao de conversao biossintética da testosterona para di-hidro- testosterona em um mamifero e composiçao farmacèutica - Google Patents
[go: Go Back, main page]

BR9407866A - Composto processos para inibiçao de 5 -redufase ou isoenzimas da mesma paratratamento de condiçoes de acne vulgar alopécia androgènica hirsutismo feminino hiperplasia prostática benigna prostatite e para o tratamento e/ou prevençao do cancer da próstata para interrupçao e reversao de alopécia androgènica e promoçao do crescimento de cabelo em um mamifero e para inibiçao de conversao biossintética da testosterona para di-hidro- testosterona em um mamifero e composiçao farmacèutica - Google Patents

Composto processos para inibiçao de 5 -redufase ou isoenzimas da mesma paratratamento de condiçoes de acne vulgar alopécia androgènica hirsutismo feminino hiperplasia prostática benigna prostatite e para o tratamento e/ou prevençao do cancer da próstata para interrupçao e reversao de alopécia androgènica e promoçao do crescimento de cabelo em um mamifero e para inibiçao de conversao biossintética da testosterona para di-hidro- testosterona em um mamifero e composiçao farmacèutica

Info

Publication number
BR9407866A
BR9407866A BR9407866A BR9407866A BR9407866A BR 9407866 A BR9407866 A BR 9407866A BR 9407866 A BR9407866 A BR 9407866A BR 9407866 A BR9407866 A BR 9407866A BR 9407866 A BR9407866 A BR 9407866A
Authority
BR
Brazil
Prior art keywords
androgenic alopecia
testosterone
mammal
inhibiting
treatment
Prior art date
Application number
BR9407866A
Other languages
English (en)
Inventor
Philippe L Durette
William K Hagmann
Thomas J Lanza Jr
Soumya P Sahoo
Gary H Rasmusson
Richard L Tolman
Derek Von Lange
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Publication of BR9407866A publication Critical patent/BR9407866A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J73/00—Steroids in which the cyclopenta[a]hydrophenanthrene skeleton has been modified by substitution of one or two carbon atoms by hetero atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J73/00—Steroids in which the cyclopenta[a]hydrophenanthrene skeleton has been modified by substitution of one or two carbon atoms by hetero atoms
    • C07J73/001—Steroids in which the cyclopenta[a]hydrophenanthrene skeleton has been modified by substitution of one or two carbon atoms by hetero atoms by one hetero atom
    • C07J73/005—Steroids in which the cyclopenta[a]hydrophenanthrene skeleton has been modified by substitution of one or two carbon atoms by hetero atoms by one hetero atom by nitrogen as hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28—Antiandrogens

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Reproductive Health (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
BR9407866A 1993-10-21 1994-10-21 Composto processos para inibiçao de 5 -redufase ou isoenzimas da mesma paratratamento de condiçoes de acne vulgar alopécia androgènica hirsutismo feminino hiperplasia prostática benigna prostatite e para o tratamento e/ou prevençao do cancer da próstata para interrupçao e reversao de alopécia androgènica e promoçao do crescimento de cabelo em um mamifero e para inibiçao de conversao biossintética da testosterona para di-hidro- testosterona em um mamifero e composiçao farmacèutica BR9407866A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14115393A 1993-10-21 1993-10-21
PCT/US1994/012071 WO1995011254A1 (en) 1993-10-21 1994-10-21 16-substituted-4-aza-androstane 5-alpha-reductase isozyme 1 inhibitors

Publications (1)

Publication Number Publication Date
BR9407866A true BR9407866A (pt) 1996-10-29

Family

ID=22494410

Family Applications (2)

Application Number Title Priority Date Filing Date
BR9407866A BR9407866A (pt) 1993-10-21 1994-10-21 Composto processos para inibiçao de 5 -redufase ou isoenzimas da mesma paratratamento de condiçoes de acne vulgar alopécia androgènica hirsutismo feminino hiperplasia prostática benigna prostatite e para o tratamento e/ou prevençao do cancer da próstata para interrupçao e reversao de alopécia androgènica e promoçao do crescimento de cabelo em um mamifero e para inibiçao de conversao biossintética da testosterona para di-hidro- testosterona em um mamifero e composiçao farmacèutica
BR1100217-4A BR1100217A (pt) 1993-10-21 1997-04-03 Composto, e, composição farmacêutica

Family Applications After (1)

Application Number Title Priority Date Filing Date
BR1100217-4A BR1100217A (pt) 1993-10-21 1997-04-03 Composto, e, composição farmacêutica

Country Status (28)

Country Link
US (4) US5739137A (pt)
EP (1) EP0724592B1 (pt)
JP (1) JP2862376B2 (pt)
KR (1) KR100363994B1 (pt)
CN (1) CN1058499C (pt)
AT (1) ATE175420T1 (pt)
BG (1) BG61978B1 (pt)
BR (2) BR9407866A (pt)
CA (1) CA2173863C (pt)
CY (1) CY2136B1 (pt)
CZ (1) CZ292614B6 (pt)
DE (1) DE69415824T2 (pt)
DK (1) DK0724592T3 (pt)
ES (1) ES2125495T3 (pt)
FI (1) FI961697L (pt)
HU (1) HUT74613A (pt)
IL (1) IL111357A (pt)
LV (2) LV11622B (pt)
NO (1) NO308037B1 (pt)
NZ (1) NZ275293A (pt)
PL (1) PL179611B1 (pt)
RO (1) RO116197B1 (pt)
RU (1) RU2142956C1 (pt)
SK (1) SK281645B6 (pt)
TW (1) TW413682B (pt)
UA (1) UA44257C2 (pt)
WO (1) WO1995011254A1 (pt)
ZA (1) ZA948285B (pt)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5547957A (en) * 1993-10-15 1996-08-20 Merck & Co., Inc. Method of treating androgenic alopecia with 5-α reductase inhibitors
BR9407866A (pt) 1993-10-21 1996-10-29 Merck & Co Inc Composto processos para inibiçao de 5 -redufase ou isoenzimas da mesma paratratamento de condiçoes de acne vulgar alopécia androgènica hirsutismo feminino hiperplasia prostática benigna prostatite e para o tratamento e/ou prevençao do cancer da próstata para interrupçao e reversao de alopécia androgènica e promoçao do crescimento de cabelo em um mamifero e para inibiçao de conversao biossintética da testosterona para di-hidro- testosterona em um mamifero e composiçao farmacèutica
US5470976A (en) * 1994-09-07 1995-11-28 Merck & Co., Inc. Process for the stereoselective reduction of steroid enelactams
AU694576B2 (en) * 1994-10-21 1998-07-23 Merck & Co., Inc. Combination method for acne treatment
US5543417A (en) * 1994-10-21 1996-08-06 Merck & Co., Inc. Combination method of treating acne using 4-AZA-5α-cholestan-ones and 4-AZA-5α-androstan-ones as selective 5α-reductase inhibitors with anti-bacterial, keratolytic, or anti-inflammatory agents
US5886005A (en) * 1995-01-17 1999-03-23 Merck & Co., Inc. 4-Aza-19-norandrostane derivatives
EP0862436A1 (en) * 1995-10-19 1998-09-09 Merck & Co., Inc. 16-substituted-6-aza-steroid 5-alpha-reductase inhibitors
US5872126A (en) * 1996-09-06 1999-02-16 Merck & Co., Inc. Methods and compositions for treating preterm labor
US5945412A (en) * 1996-12-09 1999-08-31 Merck & Co., Inc. Methods and compositions for preventing and treating bone loss
CA2283098A1 (en) * 1997-03-17 1998-09-24 Merck & Co., Inc. Methods and compositions for treating polycystic ovary syndrome
US5935968A (en) * 1997-03-17 1999-08-10 Merck & Co., Inc. Methods for treating polycystic ovary syndrome
US5942519A (en) * 1997-10-28 1999-08-24 Merck & Co., Inc. Prevention of precipitated acute urinary retention
US6187925B1 (en) * 1997-12-23 2001-02-13 Merck & Co., Inc. Intermediates and process for the synthesis of azasteroids
AR016257A1 (es) * 1998-05-14 2001-06-20 Merck & Co Inc Proceso para la sintesis estereoselectiva de ariloxi-4-aza-5alfa-androstan-3-onas, 16 alfa y 16 beta-sustituidas e insustituidas, e intermediariosobtenidos en dicho proceso.
WO1999058550A1 (en) * 1998-05-14 1999-11-18 Merck & Co., Inc. 7beta-methyl-16beta-((4-methylsulfonyl)-phenoxy)-4-aza-5alpha-androst-1-en-3-one as a 5-alpha-reductase isozyme 1 inhibitor
US6902721B1 (en) 1998-07-10 2005-06-07 Osteoscreen, Inc. Inhibitors of proteasomal activity for stimulating bone growth
US6462019B1 (en) 1998-07-10 2002-10-08 Osteoscreen, Inc. Inhibitors of proteasomal activity and production for stimulating bone growth
US6838436B1 (en) 1998-07-10 2005-01-04 Osteoscreen Inc. Inhibitors of proteasomal activity for stimulating bone growth
CA2338298A1 (en) * 1998-07-29 2000-02-10 Merck & Co., Inc. Tricyclic compounds
US6268377B1 (en) 1998-09-28 2001-07-31 Merck & Co., Inc. Method for treating androgen-related conditions
US20020198215A1 (en) * 2000-10-23 2002-12-26 Lino Tavares Terazosin transdermal device and methods
RU2288720C2 (ru) * 2001-05-15 2006-12-10 Тайсо Фармасьютикал Ко., Лтд. Жидкая композиция, содержащая миноксидил
EP1734963A4 (en) * 2004-04-02 2008-06-18 Merck & Co Inc METHOD FOR TREATING PEOPLE WITH METABOLIC AND ANTHROPOMETRIC DISORDER
CA2602386A1 (en) * 2005-03-25 2006-10-05 Merck & Co., Inc. Method of treating men with testosterone supplement and 5alpha-reductase inhibitor
US20060241696A1 (en) * 2005-04-26 2006-10-26 Stjepan Krco Method of limiting hair loss and promoting hair growth
FR2910002B1 (fr) * 2006-12-13 2009-01-30 Sanofi Aventis Sa Nouveau procede pour l'obtention diastereoselective d'une amine primaire chirale sur un steroide
RU2364402C1 (ru) * 2008-04-28 2009-08-20 Государственное образовательное учреждение высшего профессионального образования Московская медицинская академия им. И.М. Сеченова Федерального агентства по здравоохранению и социальному развитию (ГОУВПО ММА им. И.М. Сеченова Росздрава) Способ лечения больных хроническим простатитом
GB201102913D0 (en) 2011-02-18 2011-04-06 Univ Birmingham Novel therapeutic
TWI593411B (zh) 2013-04-30 2017-08-01 徐懷山 組合物於製備抑制雄性素受體有關之功能及治療雄性素 受體相關之疾病的藥物之用途

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU527030B2 (en) * 1978-04-13 1983-02-10 Merck & Co., Inc. 4-aza-17-substituted-5a-androstan-3-ones
US4377584A (en) * 1978-04-13 1983-03-22 Merck & Co., Inc. 4-Aza-17β-substituted-5α-androstan-3-one-reductase inhibitors
US4220775A (en) * 1979-03-15 1980-09-02 Merck & Co., Inc. Preparation of 4-aza-17-substituted-5α-androstan-3-ones useful as 5α-reductase inhibitors
US5138063A (en) * 1984-02-27 1992-08-11 Merck & Co., Inc. 17β-methoxycarbonyl-4-aza-androsten-1-en-3-ones
US5571817A (en) * 1984-02-27 1996-11-05 Merck & Co., Inc. Methods of treating androgenic alopecia with finasteride [17β-N-mono-substituted-carbamoyl-4-aza-5-α-androst-1-en-ones]
US4760071A (en) * 1984-02-27 1988-07-26 Merck & Co., Inc. 17β-N-monosubstituted carbamoyl-4-aza-5α-androst-1-en-3-ones which are active as testosterone 5α-reductase inhibitors
US5151429A (en) * 1984-02-27 1992-09-29 Merck & Co., Inc. 17β-acyl-4-aza-5α-androst-1-ene-3-ones as 5α reductase inhibitors
US5120742A (en) * 1984-02-27 1992-06-09 Merck & Co., Inc. 17 β-acyl-4-aza-5 α-androst-1-ene-3-ones as 5 α-reductase inhibitors
US5049562A (en) * 1984-02-27 1991-09-17 Merck & Co., Inc. 17β-acyl-4-aza-5α-androst-1-ene-3-ones as 5α-reductase inhibitors
NZ211145A (en) * 1984-02-27 1988-10-28 Merck & Co Inc 4-aza-5-alpha-androst-1-en-3-ones and pharmaceutical compositions
US4859681A (en) * 1984-02-27 1989-08-22 Merck & Co., Inc. 17 α-Acyl-4-aza-5a-androst-1-en-3-ones as 5 alpha-reductase inhibitors
EP0285383B1 (en) * 1987-04-03 1994-03-16 Merck & Co. Inc. Treatment of prostatic carcinoma with 17beta-n-monosubstituted-carbamoyl-4-aza-5alpha-androst-1-en-3-ones
DE3888994T2 (de) * 1987-04-03 1994-11-03 Merck & Co Inc Behandlung von androgener Alopecia mit 17-beta-n-mono-substituierten-carbamoyl-4-aza-5-alpha-androst-1-en-3-onen.
US5116983A (en) * 1988-04-18 1992-05-26 Merck & Co., Inc. Dehydrogenation process intermediates
US5084574A (en) * 1988-04-18 1992-01-28 Merck & Co., Inc. Dehydrogenation process
CA2084798A1 (en) * 1991-12-17 1993-06-18 Glenn J. Gormley Method of preventing prostatic carcinoma with 17beta -acyl-4-aza-5.- androst-1-ene-3-ones
US5215894A (en) * 1992-02-25 1993-06-01 Merck & Co., Inc. Biological process for producing 17β-N-monosubstituted carbamoyl-11-oxo-4-aza-5-α-androst-3-one testosterone-5-α reductase inhibitors
GB2264494A (en) * 1992-02-25 1993-09-01 Merck & Co Inc 17b-n-monosubstituted carbamoyl-11-oxo-4-aza-5-a-androst-1-en-3-one testosterone-5-alpha reductase inhibitors
WO1993023039A1 (en) * 1992-05-20 1993-11-25 Merck & Co., Inc. Substituted 4-aza-5a-androstan-ones as 5a-reductase inhibitors
SK137994A3 (en) * 1992-05-20 1995-04-12 Merck & Co Inc 7-beta-substituted-4-aza-5-alpha-cholestan-ons their using for production of pharmaceutical agent and pharmaceutical agent containing them
AU674145B2 (en) * 1992-05-20 1996-12-12 Merck & Co., Inc. New 17-ester, amide, and ketone derivatives of 3-oxo-4-azasteroids as 5a-reductase inhibitors
UA35589C2 (uk) * 1992-05-21 2001-04-16 Андорешерш Інк. ІНГІБІТОРИ ТЕСТОСТЕРОН 5-<font face="Symbol">a</font>-РЕДУКТАЗИ, ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ ТА СПОСІБ ІНГІБУВАННЯ АКТИВНОСТІ ТЕСТОСТЕРОН 5-<font face="Symbol">a</font>-РЕДУКТАЗИ
GB9216329D0 (en) * 1992-07-31 1992-09-16 Erba Carlo Spa 17beta-substituted 4-aza-5alpha-androstan-3-one derivatives
GB9216284D0 (en) * 1992-07-31 1992-09-16 Erba Carlo Spa Fluorinated 17beta-substituted 4-aza-5alpha-androstane-3-one derivatives
US5278159A (en) * 1992-10-06 1994-01-11 Merck & Co., Inc. Aryl ester derivatives of 3-oxo-4-aza-androstane 17-β-carboxylates as 5-α-reductase inhibitors
US5380728A (en) * 1993-02-10 1995-01-10 Merck & Co., Inc. Aldehyde metabolite of 17β-N-monosubstituted-carbamoyl-4-aza-5α-a
US5407944A (en) * 1993-02-19 1995-04-18 Goldman; Boris E. Compositions and methods for promoting hair growth
US5359071A (en) * 1993-03-12 1994-10-25 Merck & Co., Inc. 15-substituted 4-azasteroids
TW369521B (en) * 1993-09-17 1999-09-11 Smithkline Beecham Corp Androstenone derivative
US5547957A (en) * 1993-10-15 1996-08-20 Merck & Co., Inc. Method of treating androgenic alopecia with 5-α reductase inhibitors
BR9407866A (pt) * 1993-10-21 1996-10-29 Merck & Co Inc Composto processos para inibiçao de 5 -redufase ou isoenzimas da mesma paratratamento de condiçoes de acne vulgar alopécia androgènica hirsutismo feminino hiperplasia prostática benigna prostatite e para o tratamento e/ou prevençao do cancer da próstata para interrupçao e reversao de alopécia androgènica e promoçao do crescimento de cabelo em um mamifero e para inibiçao de conversao biossintética da testosterona para di-hidro- testosterona em um mamifero e composiçao farmacèutica
US5525608A (en) * 1994-04-20 1996-06-11 Merck & Co., Inc. 17b-aryl-4-aza-steroid derivatives useful as 5-alpha-reductase inhibitors
US5512555A (en) * 1994-07-21 1996-04-30 Merck & Co., Inc. Method of treating sweat-related conditions using finasteride, epristeride and a cholestan-3-one
US5543417A (en) * 1994-10-21 1996-08-06 Merck & Co., Inc. Combination method of treating acne using 4-AZA-5α-cholestan-ones and 4-AZA-5α-androstan-ones as selective 5α-reductase inhibitors with anti-bacterial, keratolytic, or anti-inflammatory agents

Also Published As

Publication number Publication date
ES2125495T3 (es) 1999-03-01
DK0724592T3 (da) 1999-08-30
BG61978B1 (bg) 1998-11-30
RU2142956C1 (ru) 1999-12-20
RO116197B1 (ro) 2000-11-30
NO308037B1 (no) 2000-07-10
BR1100217A (pt) 1999-11-09
ATE175420T1 (de) 1999-01-15
LV12316B (en) 1999-11-20
JPH09511213A (ja) 1997-11-11
UA44257C2 (uk) 2002-02-15
EP0724592A1 (en) 1996-08-07
NZ275293A (en) 1998-02-26
LV12316A (lv) 1999-07-20
KR960705839A (ko) 1996-11-08
LV11622A (lv) 1996-12-20
AU680063B2 (en) 1997-07-17
HK1009047A1 (en) 1999-05-21
TW413682B (en) 2000-12-01
NO961575D0 (no) 1996-04-19
FI961697A7 (fi) 1996-04-18
IL111357A (en) 2001-01-28
CZ292614B6 (cs) 2003-11-12
FI961697A0 (fi) 1996-04-18
IL111357A0 (en) 1994-12-29
SK49696A3 (en) 1996-10-02
ZA948285B (en) 1995-06-19
SK281645B6 (sk) 2001-06-11
JP2862376B2 (ja) 1999-03-03
PL179611B1 (pl) 2000-10-31
CZ122896A3 (en) 1997-01-15
EP0724592B1 (en) 1999-01-07
HUT74613A (en) 1997-01-28
CA2173863A1 (en) 1995-04-27
US5910497A (en) 1999-06-08
CY2136B1 (en) 2002-06-21
PL314039A1 (en) 1996-08-05
BG100516A (bg) 1996-11-29
WO1995011254A1 (en) 1995-04-27
CN1136318A (zh) 1996-11-20
DE69415824T2 (de) 1999-08-05
CA2173863C (en) 2003-05-13
CN1058499C (zh) 2000-11-15
AU8086194A (en) 1995-05-08
US5719158A (en) 1998-02-17
KR100363994B1 (ko) 2003-04-10
US5739137A (en) 1998-04-14
LV11622B (en) 1997-06-20
HU9601037D0 (en) 1996-06-28
NO961575L (no) 1996-04-19
US6204273B1 (en) 2001-03-20
DE69415824D1 (de) 1999-02-18
FI961697L (fi) 1996-04-18

Similar Documents

Publication Publication Date Title
BR9407866A (pt) Composto processos para inibiçao de 5 -redufase ou isoenzimas da mesma paratratamento de condiçoes de acne vulgar alopécia androgènica hirsutismo feminino hiperplasia prostática benigna prostatite e para o tratamento e/ou prevençao do cancer da próstata para interrupçao e reversao de alopécia androgènica e promoçao do crescimento de cabelo em um mamifero e para inibiçao de conversao biossintética da testosterona para di-hidro- testosterona em um mamifero e composiçao farmacèutica
GEP20094660B (en) Pyran-2-ones and 5,6-dihydropyran-2-ones useful for treating hyperplasia and other diseases
MY123960A (en) Method of treating androgenic alopecia with 5- alpha reductase inhibitors.
HU9600976D0 (en) Method of treating androgenic alopecia with 5-alpha reductase inhibitors
ATE178795T1 (de) 7-substituierte-4-aza-steroid-derivate als 5- alpha-reductase-hemmer
WO2000007576A3 (en) INHIBITORS OF TYPE 3 3α-HYDROSTEROID DEHYDROGENASE
ES2149208T3 (es) Inhibidores 4-azaesteroides de 5-alfa-reductasa.
LV12721A (lv) 17-beta-carboxanilides of 4-aza-5-alpha-androstan-3-ones as 5-alpha-reductase inhibitors
DE69326008D1 (de) 17-amino-substituierte 4-azasteroide als 5-alpha-reductase inhibitoren
EP0747048A3 (en) Diterpenes and flavonoids as 5-alpha-reductase inhibitors
DE69519728D1 (de) 17 beta-aryl-4-aza-steroidderivate
ES2160842T3 (es) Derivados de esteroides 17-alquil-4-aza-7-sustituidos.
WO2005079164A1 (ja) ５α−リダクターゼ阻害剤
WO2005079164A3 (ja) ５α−リダクターゼ阻害剤
YU12295A (sh) 16-supstituisani-4-aza-androstani inhibitori 5-alfa-reduktaze izozima 1

Legal Events

Date Code Title Description
FA Application withdrawn